Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Guidetti A, et al. Among authors: farina l. Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19. Clin Cancer Res. 2014. PMID: 25239609 Clinical Trial.
Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes.
Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, Cuttica A, Rosato R, Farina L, Boccadoro M, Benedetti F, Pileri A, Tarella C. Corradini P, et al. Among authors: farina l. J Clin Oncol. 2004 Apr 15;22(8):1460-8. doi: 10.1200/JCO.2004.10.054. J Clin Oncol. 2004. PMID: 15084619 Clinical Trial.
Immune-mediated attack in relapsed Hodgkin's lymphoma.
Corradini P, Farina L. Corradini P, et al. Among authors: farina l. Lancet. 2005 Jun 4-10;365(9475):1906-8. doi: 10.1016/S0140-6736(05)66636-6. Lancet. 2005. PMID: 15936404 No abstract available.
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V, Farina L, Milanesi M, Longoni P, Carlo-Stella C, Corradini P. Dodero A, et al. Among authors: farina l. Exp Hematol. 2005 Aug;33(8):920-7. doi: 10.1016/j.exphem.2005.05.009. Exp Hematol. 2005. PMID: 16038785 Free article.
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P, Ciceri F, Bacigalupo A, Dodero A, Lucesole M, Patriarca F, Rambaldi A, Scimè R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A. Corradini P, et al. Among authors: farina l. J Clin Oncol. 2005 Sep 20;23(27):6690-8. doi: 10.1200/JCO.2005.07.070. J Clin Oncol. 2005. PMID: 16170177 Clinical Trial.
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.
Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo. Corradini P, et al. Among authors: farina l. Leukemia. 2007 Nov;21(11):2316-23. doi: 10.1038/sj.leu.2404822. Epub 2007 Jun 28. Leukemia. 2007. PMID: 17597807
436 results